Evaluation of CD71 Expression in Acute Leukemia in Egyptian Patients

Title: Evaluation of CD71 Expression in Acute Leukemia in Egyptian Patients

Authors: Yasmin Nabil El-Sakhawy, Shaimaa Abdelmalik Pessar, Noha Hussein Boshnak

DOI: https://dx.doi.org/10.18535/jmscr/v4i10.41

Abstract

References

Corresponding Author

Abstract

Background: CD71 or transferrin receptor is an integral membrane protein that mediates cellular iron uptake. It has been identified as a proliferation marker being expressed on many solid tumours as well as hematological neoplasms. Hence, CD 71 expression was assessed as a flow cytometric marker for leukemia and lymphoproliferative neoplasms. However, only few studies aimed to address its diagnostic and prognostic implications as well as its relation to clinical and laboratory markers. So, our study aimed at evaluation of the significance of CD71 (transferrin receptor 1, TfR-1) as a flow cytometric marker for the diagnosis of acute leukemia (AL).

Methods: Seventy two patients diagnosed as acute leukemia; fifty six acute myeloid leukemia (AML) and sixteen Precursor B acute lymphoblastic leukemia (pre B ALL) were enrolled in the study and assessed for CD71 expression on blast cells by flow cytometry.

Results: CD71expression was found to be significantly higher in acute myeloid leukemias than precursor B lymphoblastic leukemia (p:0.000) while median of MFI of CD71 was significantly higher in B lymphoblastic leukemia (p:0.016) than acute myeloid leukemia with the most remarkable expression was on poorly differentiated AML FAB subtypes.

Conclusion: CD71 may be useful for the differential diagnosis of precursor B-ALL from AML in addition it could be useful in the evaluation of differentiation stage in case of AML.

Key Words: CD71, Transferrin receptor, Acute Leukemia, Poorly differentiated AML, Precursor B ALL.

References

1. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V, Fiere D (2004). Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22(20):4075–4086.

2. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. (2008) Hematol Am Soc Hematol Educ Program 1–11

3. Arber DA. Algorithmic approach to the classification of acute leukemia: United States & Canadian Academy of Pathology (USCAP) Web site. http://www. uscap.org/site,/98th/pdf/companion21h02.pdf. Accessed June 4, 2010.

4. Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004; 36:2137–2143.

5. OpenUrlSargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem. 2005;12:2683–2693.

6. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31:1111–1137.

7. Sieff C, Bicknell D, Caine G, et al. Changes in cell surface antigen expression during hemopoietic differentiation. Blood. 1982;60:703–713.

8. Lesley J, Hyman R, Schulte R, et al. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol. 1984;83:14–25.

9. Nakahata T, Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma. 1994;13:401–409.

10. Kondo K, Noguchi M, Mukai K et al. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest. 1990;97:1367–1371.

11. Zborovskaya I, Gasparian A, Kitaeva M et al. Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor. Clin Exp Metastasis. 1996;14:490–500.

12. Seymour GJ, Walsh MD, Lavin MF, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res. 1987;15:341–344.

13. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett. 2006;238:188–196.

14. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer. 2004;40:1418–1422.

15. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer. 1981;27:329–334.

16. Habashy HO, Powe DG, Staka CG et al. Transferrin receptor (cd71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119:283–293.

17. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg. 1990;72:941–945.

18. Barnett D, Wilson GA, Lawrence AC, Buckley GA. Transferrin receptor expression in the leukaemias and lymphoproliferative disorders. Clin Lab Haematol. 1987;9:361–370.

19. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36:539–545.

20. Taetle R, Ralph S, Smedsrud S, Trowbridge I. Regulation of transferrin receptor expression in myeloid leukemia cells. Blood. 1987;70:852–859.

21. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144–158.

22. Das Gupta A, Patil J, Shah VI. Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count & immunophenotype. Indian J Med Res. 1996;104:226–233.

23. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983;1:498–501.

24. Brooks D, Taylor C, Dos SB et al. Phase Ia trial of murine immunoglobulin a antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259–1265.

25. Yu Y, Kovacevic Z, Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6(16):1982–1994.

26. Glasova M, Konikova E, Stasakova J, Babusikova O. The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells. Neoplasma. 1998;45:88–95.

27. Koehler M, Behm F, Hancock M, Pui CH. Expression of activation antigens cd38 and cd71 is not clinically important in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:41–45.

28. Qian Liu , Mangju Wang , Yang Hu , Haizhou Xing , Xue Chen , Ying Zhang , Ping Zhu. The signifi cance of CD71 Expression by Flow Cytometry in the Diagnosis of Acute Leukemia. Leukemia & Lymphoma. 2014 Apr;55(4):892-8.

29. Chang-Jing G. Yeha, Colin G. Taylorb, W. Page Faulka. Transferrin Binding by Peripheral Blood Mononuclear Cells in Human Lymphomas, Myelomas and Leukemias. Vox Sang. 1984; 46: 217-223.

30. Loisel S, Andre PA, Golay J, Buchegger F, Kadouche J, Cerutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia Mol Cancer 2011; 10:42.

31. Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O (2004) A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103(5):1838–1845.

32. Wei YY, Zhang XZ, Zhang F, Li ZB, Wang NN, Liu S, Yue BH. Expression of CD71 on cell proliferation in hematologic malignancy and its correlation with Ki-67. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2015); 23(1):234–240.

33. Pande A, Dorwal P, Jain D, Tyagi N, Mehra S, Sachdev R, Raina V (2016): Expression of CD71 by flow cytometry in acute leukemias: More often seen in acute myeloid leukemia. Indian journal of path-ology and microbiology 59(3):310-313.

34. Nadia El-Menshawy, Sherin M. Abd-Aziz, Mohammed A. Ebrahim, Nader El-Malky. Impact of cellular CD71 (transferrin receptor 1) expression in Egyptian acute leukemia: correlation with clinicopa-thologic features. Comp Clin Pathol. Published online 20 January 2016. DOI 10.1007/s00580-015-2213-x.

35. Park S, Picard F, Dreyfus F. Erythrole-ukemia: a need for a new definition. Leukemia 2002;16(8):1399-1401.

36. Płoszyńska A, Ruckemann-Dziurdzińska K, Jóźwik A, et al. Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia. Folia Histochemica et Cytobiologica 2012;50(2):304–311.

37. Kollia P, Stavroyianni N, Stamatopoulos K, Zoi K, Viniou N, Mantzourani M, Noguchi CT, Paterakis G, Abazis D, Pangalos C, Loukopoulos D, Yataganas X (2001) Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia. Br J Haematol 115(1):19–24.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 12 December 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search